Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Domenick Sorresso

Pulmonary Disease Hudson, FL Medical Doctor

NPI 1013917160 CMS profile 534557

7614 Jacque Rd Ste C, Hudson, FL 34667

Open in the dashboard

General payments

$16,654

452 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Domenick Sorresso of Hudson, FL is reported in the CMS Open Payments database as having received $16,654 across 452 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,356 104
2024 General $1,527 61
2023 General $8,323 74
2022 General $1,063 52
2021 General $995 46
2020 General $1,288 55
2019 General $1,102 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Domenick Sorresso
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Domenick Sorresso were reported at $2,356. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Domenick Sorresso Pulmonary Disease median Middle half National median
2019 $1,102 $377 $109–$1,340 $163
2020 $1,288 $230 $56–$907 $114
2021 $995 $269 $68–$1,072 $132
2022 $1,063 $390 $100–$1,457 $149
2023 $8,323 $419 $114–$1,659 $160
2024 $1,527 $476 $123–$1,818 $164
2025 $2,356 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $7,113 11 payments
  2. GlaxoSmithKline, LLC. $1,775 91 payments
  3. AstraZeneca Pharmaceuticals LP $1,652 88 payments
  4. Actelion Pharmaceuticals US, Inc. $1,183 56 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,176 58 payments
  6. Insmed, Inc. $522 22 payments
  7. Genzyme Corporation $517 16 payments
  8. Electromed, Inc. $417 31 payments
  9. United Therapeutics Corporation $281 8 payments
  10. Grifols USA, LLC $262 11 payments
  11. Other $1,756 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,243 434 payments
  2. Education $6,430 12 payments
  3. Travel and Lodging $880 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $4,113 10 payments
  2. ION $3,000 1 payment
  3. OFEV $1,221 63 payments
  4. OPSUMIT $1,100 51 payments
  5. TRELEGY ELLIPTA $1,096 52 payments
  6. UPTRAVI $953 44 payments
  7. DUPIXENT $657 18 payments
  8. Arikayce $506 21 payments
  9. BREZTRI $451 21 payments
  10. FASENRA $408 20 payments
  11. Other $5,165 240 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,368

Median for Pulmonary Disease: 936

Drug cost

$2,021,776

Median for Pulmonary Disease: $487,987

Branded share of claims

57.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 49 $630,881
Opsumit Macitentan Brand 37 $466,395
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 264 $263,139
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 193 $212,881
Prolastin C Alpha-1-Proteinase Inhibitor Brand 15 $201,435
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 44 $49,851
Breo Ellipta Fluticasone/Vilanterol Brand 67 $39,785
Symbicort Budesonide/Formoterol Fumarate Brand 88 $32,650
Spiriva Respimat Tiotropium Bromide Brand 24 $25,853
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $19,375

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$172,475

Of which drugs: $138

Medicare patients

746

Average age 76

Services billed

3,633

394 women, 352 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 58%
COPD 56%
Chronic kidney disease 46%
Diabetes 39%
Atrial fibrillation 37%
Heart failure 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 1,100 $108
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 14 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $218
  • Regeneron Healthcare Solutions, Inc. $63
$282 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $172
$172 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $168
$168 264 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $110
$110 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $86
$86 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

452 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record